CDI 45205
Alternative Names: CDI-45205Latest Information Update: 10 Apr 2024
At a glance
- Originator Kansas state university research foundation
- Developer Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors; Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Coronavirus infections; COVID 2019 infections
Most Recent Events
- 29 Mar 2024 Cocrystal Pharma and Kansas State University Research Foundation terminates its Licensing agreement for CDI 45205
- 01 Dec 2021 Cocrystal Pharma Inc plans a phase I trial for COVID-2019 infections (In volunteers) (Inhalation), in 2022
- 01 Dec 2021 Cocrystal Pharma Inc plans a phase II trial for COVID-2019 infections (Inhalation), in 2022